Dr. Dandoy on TMA Risk After Pediatric Allogeneic Stem Cell Transplant

Christopher E. Dandoy, MD, MSc
Published: Saturday, Feb 23, 2019



Christopher E. Dandoy, MD, MSc, assistant professor of pediatrics at Cincinnati Children’s Hospital, says that patients undergoing allogeneic stem cell transplant are at high-risk of developing thrombotic microangiopathy (TMA).

TMA occurs in 30% of these patients and can occur as early as 7 days after transplant. When it is identified to be present, the patient can be properly treated right away, Dandoy notes.

Tools from these data presented at the 2019 Transplantation & Cellular Therapy Meetings as well as tools from other data can be used to identify these patients even earlier.

<<< 2019 Transplantation and Cellular Therapy Meetings


Christopher E. Dandoy, MD, MSc, assistant professor of pediatrics at Cincinnati Children’s Hospital, says that patients undergoing allogeneic stem cell transplant are at high-risk of developing thrombotic microangiopathy (TMA).

TMA occurs in 30% of these patients and can occur as early as 7 days after transplant. When it is identified to be present, the patient can be properly treated right away, Dandoy notes.

Tools from these data presented at the 2019 Transplantation & Cellular Therapy Meetings as well as tools from other data can be used to identify these patients even earlier.

<<< 2019 Transplantation and Cellular Therapy Meetings

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x